Family Medicine pp 1006-1016 | Cite as

Selected Disorders of the Blood and Hematopoietic System

  • Paul M. Paulman
  • Nancy Wolf-Gillespie
  • Layne A. Prest


Hemophilia A is an autosomal recessive X-linked deficiency of factor VIII. Because of the mode of transmission and gene expression, males have hemophilia A, and females are usually asymptomatic carriers of the hemophilia A gene. All daughters of a hemophiliac father are carriers of the hemophilia A gene; all his sons are normal. The children of a female hemophilia A carrier have a 50% chance of being affected by the gene. Hemophilia A affects approximately 1 in 10,000 to 20,000 males in the United States.1


Sickle Cell Anemia Factor Viii Sickle Cell Disseminate Intravascular Coagulation Disseminate Intravascular Coagulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Monsour PA, Kruger B J, Harden PA. Prevalence and detection of patients with bleeding disorders. Aust Dent J 1986;31:104–11.PubMedCrossRefGoogle Scholar
  2. 2.
    Aronstom A. Hemophilic bleeding. East Sussex, UK: Balliere Tindall, 1985.Google Scholar
  3. 3.
    Williams WJ, Beutler E, Erslev AJ, Lichtman MA. Hematology. New York: McGraw-Hill, 1990.Google Scholar
  4. 4.
    Mannucci PM. Desmopressin (DDAVP) for treatment of hemophilia. Prog Hemost Thromb 1986;8:19–45.PubMedGoogle Scholar
  5. 5.
    Colleen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980;43:77–89.Google Scholar
  6. 6.
    Brocker-Vriende AJHT, Briët E, Quadt R. Genotype assignment of haemophilia A by use of intragenic and extragenic restriction fragment length polymorphisms. Thromb Haemost 1987;57:131–6.Google Scholar
  7. 7.
    Graham JB, Green PP, McGraw RA, Davis LM. Application of molecular genetics to prenatal diagnosis and carrier detection in the hemophilias: some limitations. Blood 1985;66:759–64.PubMedGoogle Scholar
  8. 8.
    Leahey M, Wright LM. Intervening with families with chronic illness. Farn Syst Med 1985;3:60–9.CrossRefGoogle Scholar
  9. 9.
    Bowie EJW, Didisheim P, Thompson JH, Owen CA. von Willebrand’s disease: a critical review. Hematol Rev 1968;1:1–50.Google Scholar
  10. 10.
    Ngo KY, Glotz VT, Koziol JA, et al. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease. Proc Natl Acad Sci USA 1988;85:2753–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Batlle J, Fernanda M, Lopez-Fernandez F, et al. Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individuals. Blood 1987;70:173–6.PubMedGoogle Scholar
  12. 12.
    Harrison RL, McKee PA. Estrogen stimulates von Willebrand factor production by cultured endothelial cells. Blood 1984;63:657–65.PubMedGoogle Scholar
  13. 13.
    Ginsburg D, Handin RI, Bonthron DT, et al. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985;228: 1401–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Bertina RM, Van Der Marel-Van Nieuwkoop W, Dubbeldam J, Boekhout-Mussert RJ, Veitkamp JJ. New method for the rapid detection of vitamin K deficiency. Clin Chim Acta 1980;105:93–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Committee on Nutrition. Vitamin K supplementation for infants receiving milk substitute infant formulas and for those with fat malabsorption. Pediatrics 1971;48:483–6.Google Scholar
  16. 16.
    Lusher JM, Iyer R. Ideopathic thrombocytopenic purpura in children. Semin Thromb Hemost 1977;3:175–99.PubMedGoogle Scholar
  17. 17.
    DiFino SM, Lachant NA, Kirshner JJ, Gottlieb AJ. Adult idiopathic thrombocytopenic purpura: clinical findings and response to therapy. Am J Med 1980;69:430–42.PubMedCrossRefGoogle Scholar
  18. 18.
    McMillan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1981;304:1135–47.PubMedCrossRefGoogle Scholar
  19. 19.
    Akwari OE, Itani KMF, Coleman RE, Rosse WF. Splenectomy for primary and recurrent immune thrombocytopenic purpura (ITP): current criteria for patient selection and results. Ann Surg 1987;206:529–39.PubMedCrossRefGoogle Scholar
  20. 20.
    Nalli G, Sajeva R, Carnevale MG, Ascari E. Ranazol therapy for ideopathic thrombocytopenic purpura (ITP). Haematologica 1988; 73:55–7.PubMedGoogle Scholar
  21. 21.
    Awidi AS, El-Khateeb MS, Abu Khalaf MM, Tarawneh MS, Shannak MS. A controlled trial of steroids and splenectomy versus bolus intravenous vincristine in the treatment of adult idiopathic thrombocytopenic purpura. Curr Ther Res 1986;40:809–13.Google Scholar
  22. 22.
    Bussel JB, Pham LC. Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: review of the literature. Vox Sang 1987;52:206–11.PubMedCrossRefGoogle Scholar
  23. 23.
    Blanchette VS, Hogan VA, McCombie NE, et al. Intensive plasma exchange therapy in ten patients with idiopathic thrombocytopenic purpura. Transfusion 1984;24:388–94.PubMedCrossRefGoogle Scholar
  24. 24.
    Strother SV, Zuckerman KS, LoBuglio AF. Colchicine therapy for refractory idiopathic thrombocytopenic purpura. Arch Intern Med 1984;144:2198–2200.PubMedCrossRefGoogle Scholar
  25. 25.
    Clarkson SB, Bussel JB, Kimberly RP, et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc receptor antibody. N Engl J Med 1986;314:1236–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Bird RM, Hammarsten JF, Marshall RA, Robinson RR. A study of hereditary hemorrhagic telangiectonia. N Engl J Med 1957;257: 105–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Bird RM, Jaques WE. Vascular lesion of hereditary hemorrhagic telangiestasia. N Engl J Med 1959;260:597–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Tattersall RN, Seville R. purpura. Q J Med 1950;19:151–9.Google Scholar
  29. 29.
    Levinsky RJ, Barratt TM. IgA immune complexes in Henoch-Schonlein purpura. Lancet 1979;2 (8152):1100–3.PubMedCrossRefGoogle Scholar
  30. 30.
    Allen DM, Diamond LK, Howell DA. Anaphylactoid purpura in children (Schonlein-Henoch syndrome): review with a follow-up of the renal complications. AMA J Dis Child 1960;99:833–54.PubMedGoogle Scholar
  31. 31.
    Kugelman IN. Cortisone in allergic purpura of children. NY State J Med 1951;51:2504–6.Google Scholar
  32. 32.
    Szelid Z, Bereczky J, Nagymanyai Z, Ruszinhow V. Heparin prophylaxis of Henoch-Schonlein nephropathy. Acta Paediatr Hung 1986;27:57–60.PubMedGoogle Scholar
  33. 33.
    Lackner H, Karpatkin S. On the “easy bruising“ syndrome with normal platelet count: a study of 75 patients. Ann Intern Med 1975;83:190–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Coleman RW, Robboy SJ, Minna JD. Disseminated intravascular coagulation: a reappraisal. Annu Rev Med 1979;30:359–74.CrossRefGoogle Scholar
  35. 35.
    Coleman RW, Robboy S J, Minna JD. Disseminated intravascular coagulation (DIC): an approach. Am J Med 1972;52:679–89.CrossRefGoogle Scholar
  36. 36.
    Williams WJ, Beutler E, Erslen AJ, Lichtman MA. Hematology. New York: McGraw-Hill, 1990.Google Scholar
  37. 37.
    Shoenfeld Y, Modan M, Berliner S, et al. The mechanism of benign hereditary neutropenia. Arch Intern Med 1982;April(4):142;797–9.Google Scholar
  38. 38.
    Dale DC, Guerry D, Wewerka JR, Bull JM, Chusid MJ. Chronic neutropenia. Medicine (Baltimore) 1979;58:128–44.Google Scholar
  39. 39.
    Murphy MF, Metcalfe P, Waters AH, et al. Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol 1987;66:337–40.PubMedCrossRefGoogle Scholar
  40. 40.
    Pincus SH, Boxer LA, Stossel TP. Chronic neutropenia in childhood. Am J Med 1976;61:849–61.PubMedCrossRefGoogle Scholar
  41. 41.
    Lakos A, Timar L. Treatment of idiopathic chronic neutropenia with high-dose intravenous immunoglobulin. Pediatr Forum 1987; 141:12–3.Google Scholar
  42. 42.
    Van der Veen JPW, Hack CE, Engelfriet CP, Pegels JG, von dem Borne AEG. Chronic idiopathic and secondary neutropenia: clinical and serological investigations. Br J Haematol 1986;63:161–71.PubMedCrossRefGoogle Scholar
  43. 43.
    Conway LT, Clay ME, Kline WE, Ramsay NKC, Krivit W, McCullough J. Natural history of primary autoimmune neutropenia in infancy. Pediatrics 1987;79:728–33.PubMedGoogle Scholar
  44. 44.
    Bussel J, Lalezari P, Fikrig S. Intravenous treatment with gammaglobulin of autoimmune neutropenia of infancy. J Pediatr 1988;112:298–301.PubMedCrossRefGoogle Scholar
  45. 45.
    Lalevari P, Murphy GB, Allen FH. NB1, a new neutrophil-specific antigen involved in the pathogenesis of neonatal neutropenia. J Clin Invest 1971;50:1108–15.CrossRefGoogle Scholar
  46. 46.
    Minchinton RM, McGrath KM. Alloimmune neonatal neutropenia—a neglected diagnosis. Med J Aust 1987;147:139–41.PubMedGoogle Scholar
  47. 47.
    Dale DC, Hammond WP. Cyclic neutropenia: a clinical review. Blood Rev 1988;2:178–85.PubMedCrossRefGoogle Scholar
  48. 48.
    Williams WJ, Beutler E, Erslev AV, Lichtner MA. Hematology. New York: McGraw-Hill, 1990.Google Scholar
  49. 49.
    Vadhan RS. Clinical applications of colony-stimulating factors. Oncol Nurs Forum 1989;16 (Suppl);21–6.Google Scholar
  50. 50.
    Modan B. An epidemiological study of polycythemia vera. Blood 1965;26:657–67.PubMedGoogle Scholar
  51. 51.
    Ramamurthy RS, Yves WB. Neonatal polycythemia: one criterion for diagnosis and treatment. Pediatrics 1981;68:168–74.PubMedGoogle Scholar
  52. 52.
    Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975;12:339–51.PubMedGoogle Scholar
  53. 53.
    Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984;64:1–12.PubMedGoogle Scholar
  54. 54.
    Yu TF. Secondary gout associated with myeloproliferative diseases. Arthritis Rheum 1965;8:765–71.PubMedCrossRefGoogle Scholar
  55. 55.
    Brodsky I. Busulphan treatment of polycythemia vera. Br J Haematol 1982;52:1–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Dean J, Schechter AN. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches. N Engl J Med 1978;299:752–63.PubMedCrossRefGoogle Scholar
  57. 57.
    Heller P, Best WR, Nelson RB, Becktel J. Clinical implications of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency in hospitalized black male patients. N Engl J Med 1979;18:1001–5.CrossRefGoogle Scholar
  58. 58.
    Dunston T, Rowland R, Huntsman RG, Yawson G. Sickle-cell haemoglobin C disease and sickle-cell beta thalassanemia in white South Africans. S Afr Med J 1972;46:1423–6.PubMedGoogle Scholar
  59. 59.
    Luzzatto L. Genetics of red cells and susceptibility to malaria. Blood 1979;54:961–76.PubMedGoogle Scholar
  60. 60.
    Boghossian SH, Wright G, Webster DB, Segal AW. Investigations of host defense in patients with sickle cell disease. Br J Haematol 1985;59:523–31.PubMedCrossRefGoogle Scholar
  61. 61.
    Powars DR. Natural history of sickle cell disease—the first ten years. SeminHematol 1975;12:267–85.Google Scholar
  62. 62.
    Kark JA, Posey DM, Schumacher HR, Ruehle CJ. Sickle-cell trait as a risk factor for sudden death in physical training. N Engl J Med 1987;317:781–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Vermylen C, Robles EF, Ninane J, Cornu G. Bone marrow transplantation in five children with sickle cell anemia. Lancet 1988; 1: 1427–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med 1990;320:1037–43.CrossRefGoogle Scholar
  65. 65.
    Abraham DJ, Mehanna AS, Wireko FC, et al. Vanillin, a potential agent for the treatment of sickle cell anemia. Blood 1991 ;77:1334–41.PubMedGoogle Scholar
  66. 66.
    Levitan M. Textbook of human genetics. 3rd ed. New York: Oxford University Press, 1988.Google Scholar
  67. 67.
    Penn P. Coalitions and binding interactions in families with chronic illness. Farn Syst Med 1983;1:16–25.CrossRefGoogle Scholar
  68. 68.
    Leahey M, Wright LM. Interviewing with families with chronic disease. Farn Syst Med 1985;3:60–9.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Paul M. Paulman
  • Nancy Wolf-Gillespie
  • Layne A. Prest

There are no affiliations available

Personalised recommendations